Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

(2021) Binghe Xu et al.   LANCET ONCOLOGY

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

(2021) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

(2021) Munawar Anwar et al.   CLINICAL CANCER RESEARCH

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

(2021) Guy Heinrich Maria Jerusalem et al.   JOURNAL OF CLINICAL ONCOLOGY

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

(2020) Nancy U. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

(2020) Qitong Chen et al.   Frontiers in Oncology

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

(2020) F. Montemurro et al.   ANNALS OF ONCOLOGY

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

(2019) Rachel A. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience

(2019) Ryan T. Hughes et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Current and Evolving Role of Radiation Therapy for Central Nervous System Metastases from Breast Cancer

(2019) Shyam Tanguturi et al.   Current Oncology Reports

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database

(2018) Yi-Jun Kim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

(2017) Xin Li et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial

(2017) Anita Mahajan et al.   LANCET ONCOLOGY

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases

(2016) William Jacot et al.   BREAST CANCER RESEARCH AND TREATMENT

Activity of T-DM1 in Her2-positive breast cancer brain metastases

(2015) Rupert Bartsch et al.   CLINICAL & EXPERIMENTAL METASTASIS

Response assessment criteria for brain metastases: proposal from the RANO group

(2015) Nancy U Lin et al.   LANCET ONCOLOGY

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

(2014) I. E. Krop et al.   ANNALS OF ONCOLOGY

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

(2013) Erin M. Olson et al.   BREAST

Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases

(2012) Raffaele Addeo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

(2012) Thomas Bachelot et al.   LANCET ONCOLOGY

Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

(2011) A. M. Brufsky et al.   CLINICAL CANCER RESEARCH

Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

(2010) Martin Kocher et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH